Evidation Health operates Achievement, a privacy-forward digital health network that measures health in everyday life and powers virtual research and programs. Achievement comprises more than 4 million individuals across all 50 states and nine out of 10 ZIP codes and has enabled over 100 real-world studies across topics from COVID-19 to chronic conditions. Evidation partners with biopharma (including nine of the 10 largest companies), academic institutions, public health organizations, and medical specialty societies to generate evidence from person-generated health data. Last year the company launched its first virtual health initiatives, including Achievement for Heart Health with the American College of Cardiology and LumiHealth in collaboration with Apple and the Singapore government. Evidation plans to expand virtual health programs on Achievement, offering personalized insights, tools, and privacy-safe, double opt-in connections between research and care. Founded in 2012 and headquartered in California, the company says it will use new capital to scale these programs and translate evidence into actionable guidance for individuals. Evidation’s core product is the Achievement platform, a privacy-first direct-to-person research system that aggregates person-generated health data (PGHD) including passive sensor data, ePROs, and at-home diagnostics. The company uses this data to generate real-world evidence for life sciences, providers, payers, and public‑health partners. Evidation says its network includes nearly 4 million individuals, with participants in all 50 states and in 9 of every 10 U.S. ZIP codes, and eight of the top 10 global biopharma companies rely on its PGHD. The company plans to expand Achievement into virtual health, offering real-time insights, digital interventions, and tools to connect members with care teams; the first virtual health offerings are slated for release later this year. Evidation also intends to grow and diversify its cohort to serve additional at‑risk and disease‑specific populations. Recent partnerships and programs include the Heartline Study with Johnson & Johnson and Apple, and collaborations with the Icahn School of Medicine at Mount Sinai, BARDA, and the Bill & Melinda Gates Foundation. Evidation Health provides a data platform that ingests and analyzes individually-permissioned behavior and sensor data from smartphones, wearables, and medical devices alongside traditional medical data to generate clinically meaningful insights. The platform can ingest data from more than 100 sources including Apple Health, Fitbit, Epic, Blue Button, and Dexcom, and it currently processes more than 1 trillion data points each year across millions of individuals. It marries sensor and behavior data with insurance claims, electronic health records, diagnostic reports, and patient-reported outcomes to enable real-world research and analytics for life sciences and health care customers. Evidation also operates the Achievement app, which has more than 2 million users and serves as a large virtual research cohort. The company is using its platform to invent new measures of health across conditions such as diabetes and cognitive decline and to support work in cardiovascular disease, chronic pain, rheumatoid arthritis, migraine, depression and anxiety, fatigue, heart failure, and asthma. Future plans described include developing partnerships, adding to its array of real-world data sources, and launching novel research studies to better understand and measure how everyday behavior and health interact. Evidation Health develops a Real Life Study Platform to quantify behavior-driven health outcomes using real-world data from connected patients and devices. The company combines consumer technology, data science, outcomes research, and healthcare economics to measure product impact at large scale and accelerate virtualized pragmatic trials. Evidation works across the healthcare ecosystem with pharmaceutical companies, payers, providers, and digital health companies. It plans to further enhance capabilities in large-scale behavioral analytics, health outcomes measurement, and digital biomarker development using real-life patient data from hundreds of applications and devices. The company recently closed a $10 million financing led by Sanofi-Genzyme BioVentures, with participation from existing investors GE Ventures and B Capital Group. Evidation is privately held and headquartered in San Mateo, CA. Evidation Health develops a Real Life Study Solution and a behavior analytics platform that aggregates activity data from hundreds of clinical and consumer wearables and everyday applications. Its platform is scaled to analyze billions of data points and integrates real-world data with traditional clinical data to enable digital biomarker development, patient-reported outcomes, and measurements of disease progression. The company offers direct-to-patient study execution that it says enables 10x faster enrollment and dramatically lower costs, supporting clinical and economic utility studies. Evidation works with pharmaceutical companies, payers, providers, and digital healthcare companies across therapeutic areas to drive tailored interventions and broad, diverse participation. The company plans to scale operations to meet customer demand, continue improving its machine-learning engine for large-scale behavior data analytics and digital biomarker development, and extend its direct population reach. Evidation is privately held and headquartered in San Mateo, California.

Total raised

$259M

Funding rounds

6

Latest round

Series E

Latest activity

Mar 2021